Dana-Farber Cancer Institute
Avatar

The PROMISE of Early Detection and Interception in Myeloma

By Dana-Farber Cancer Institute FEATURING Irene Ghobrial
By Dana-Farber Cancer Institute FEATURING Irene Ghobrial
205 views
March 9, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
25:23
Houston Methodist Hospital

Whole-Body MRI: Past, Present, and Future

Feat. N. Gupta
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
28:20
PleXus Communications

Why We Should Not Treat SMM

Feat. B. Derman
04:15
Indy Hematology Review

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Feat. M. Gertz
23:34
MyCancerHaven

Experts Discuss the Diagnosis and Management of High-Risk Multiple M…

Feat. R. Vij, M. Alsina
11:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy &…

Feat. O. Landgren
32:06
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Should Patients With High-Risk SMM Be Treated Outside a Clinical Tri…

Feat. M. Gertz
32:03
Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What S…

Feat. K. Anderson
52:39
Yale Cancer Center

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Feat. A. Chari
41:54
University of Colorado Division of Hematology

Overview of Pathophysiology, Diagnosis and Management of Multiple My…

Feat. K. Sidor
22:15
5th SOHO Italy Annual Conference

SOHO Italy 2023: Multiple Myeloma Cured in 2030 - What Are the Next …

Feat. K. Anderson
10:23
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "iStopMM Study - Revised Definition of Free …

Feat. T. Einarsson Long
26:24
Dana-Farber Cancer Institute

Myeloma 101: Diagnosis, Prognosis & Risk

Feat. N. Munshi
15:21
MyCancerHaven

Response Assessment and Utility of MRD in Multiple Myeloma

Feat. R. Vij, A. Rossi
42:37
University of Colorado Department of Medicine

Multiple Myeloma in 2023: An Oncological Success Story

Feat. P. Forsberg
04:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "iStopMM Study - Risk Factors of Smoldering …

Feat. S. Thorsteinsdottir
10:13
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: MM

Feat. K. Patel
27:06
Moffitt Cancer Center

Hot Off the Press: Experts Discuss the Latest Data in Plasma Cell Dy…

Feat. R. Baz, M. Alsina, K. Shain, A. Grajales-Cruz
21:16
UChicago Medicine

Myeloma 2022: Challenges and Path Forward

Feat. A. Jakubowiak
47:04
Dana-Farber Cancer Institute

Future Directions for Novel & Next Gen Therapy in the Management…

Feat. P. Richardson